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Objectives: Cancer cachexia affects the majority of tumor patients and significantly contributes to high mortality rates in these subjects. Despite
its clinical importance, the identity of tumor-borne signals and their impact on specific peripheral organ systems, particularly the heart, remain
mostly unknown.
Methods and results: By combining differential colon cancer cell secretome profiling with large-scale cardiomyocyte phenotyping, we identified
a signature panel of seven “cachexokines”, including Bridging integrator 1, Syntaxin 7, Multiple inositol-polyphosphate phosphatase 1,
Glucosidase alpha acid, Chemokine ligand 2, Adamts like 4, and Ataxin-10, which were both sufficient and necessary to trigger cardiac atrophy
and aberrant fatty acid metabolism in cardiomyocytes. As a prototypical example, engineered secretion of Ataxin-10 from non-cachexia-inducing
cells was sufficient to induce cachexia phenotypes in cardiomyocytes, correlating with elevated Ataxin-10 serum levels in murine and human
cancer cachexia models.
Conclusions: As Ataxin-10 serum levels were also found to be elevated in human cachectic cancer patients, the identification of Ataxin-10 as
part of a cachexokine cocktail now provides a rational approach towards personalized predictive, diagnostic and therapeutic measures in cancer
cachexia.
 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Cancer-induced cachexia describes a multi-factorial disease condition
characterized by massive loss of adipose tissue and skeletal muscle
mass and is believed to be responsible for up to 30% of cancer-related
deaths in humans [1]. However, the exact causes of death and in
particular the contribution of cardiac dysfunction to deaths of these
patients is unclear [2]. Due to the phenotypic heterogeneity of cancer
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sents an immediate unmet medical need as effective and routine
therapeutic measures are still lacking to date [4].
Interestingly, the clinical severity of cancer cachexia hardly correlates
with tumor mass [5], indicating that the tumor controls peripheral
energy balance in critical host tissues via distinct signaling mediators
rather than acting as a direct “energy sink” [6]. Indeed, classical ex-
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Original articleindicating that circulating factors, rather than local tumor effects, act
as causative factors in energy wasting [7].
Since the discovery of tumor necrosis factor (TNF) alpha as the wasting-
associated “cachectin” [8], numerous cytokines have been discussed as
pro-cachectic mediators, most notably Interleukin (IL) 6 [9]. In addition,
zinc-alpha-2-glycoprotein (ZAG), also known as LMF (lipid mobilizing
factor), has been identified as an adipokine with direct lipolytic action in
white adipose tissue during murine and human cancer cachexia [10].
However, attempts to overcome cachectic energy wasting by thera-
peutically targeting these pathways remained rather disappointing and/or
not feasible [11]. For example, administration of anti-TNF alpha anti-
bodies [12] did not promote weight stabilization in human clinical trials,
overall suggesting that the cancer cachectic phenotype results either
from the combinatorial action of various factors or from yet to be
discovered, individually acting, tumor-borne mediators. Indeed, techno-
logical limitations in both appropriate read-out systems as well as spe-
cific tumor secretome detection methods have thus far prevented the
rational identification of tumor-borne signals and hampered major
progress in prognostic/diagnostic/therapeutic options in cancer cachexia.
Whereas the vast majority of previous studies have focused on the loss
of skeletal muscle and adipose tissue as phenotypic features of cancer
cachexia, recent studies suggest that other organs, i.e. the liver
[13,14] and the heart [15], also play a prominent role in systemic
cachexia. Indeed, cardiac failure is responsible for a substantial pro-
portion of cancer cachexia-induced deaths [16], and classical clinical
studies by Burch and colleagues already documented the presence of
atrophic hearts and impairment in cardiac function in cachectic tumor
patients [17]. In this respect, cancer-induced cachexia in mice was
found to disrupt myocardial structure and re-activate the fetal gene
program [18,19], correlating with hypo-innervation in the left ventricle
[20], overall suggesting that cardiac dysfunction may represent an
understudied component of systemic cancer cachexia.
Here we develop and apply cellular high throughput cardiomyocyte
phenotyping to test for the cachexia-inducing capacities of a newly
defined set of tumor-borne signaling mediators. These cachexokines
were found to be both necessary and sufficient to trigger cardiac atrophy
and metabolic dysfunction in cardiomyocytes. As a prototype, Ataxin-10
was found to be sufficient to cause cachectic cardiac phenotypes and to
signal the existence of cachexia by its serum levels in murine and human
model systems as well as in pancreatic cancer patients.
2. METHODS
2.1. Chemicals
All chemicals were purchased from Sigma Aldrich (Munich, Germany)
unless stated otherwise. Cell culture media and supplements were
from Life Technologies (Darmstadt, Germany) unless stated otherwise.
Cell culture plastic ware was obtained from BD (Heidelberg, Germany)
unless stated otherwise.
2.2. Animal experiments and treatments
Ectopic mouse model: 9e10 week old male Balb/c, C57BL6/N and Fox
Chase SCID mice were obtained from Charles River Laboratories (CRL,
Brussels, BE). Mice were injected subcutaneously into the right flank with
1.5  106 C26 colon carcinoma cells, 5  105 MC38 colon carcinoma
cells and 5  106 SW480 cells, respectively. C26 mouse experiment:
Mice were monitored for 21 days after tumor cell implantation and a
cohort of mice (6 control and 10 tumor-bearing mice) was sacrificed
every week after Pressure-Volume loopmeasurement. Echocardiography
and Pressure-Volume loop (PV loop) measurement were performed
weekly to assess the cardiac performance. Body composition was2 MOLECULAR METABOLISM- (2015) 1e12  2015 The Authors. Published by Elsevier GmbH. Thdetermined by Echo Magnetic Resonance Imaging (EchoMRI; Echo
Medical Systems, Houston, TX, USA) analysis once a week. Body weight
and food intake were determined in regular intervals. MC38 mouse
experiment: Mice were monitored for 30 days after tumor cell inoculation.
Cardiac function was assessed by weekly echocardiography. Body
composition was also measured once a week. Body weight and food
intake were determined in regular intervals. SW480 mouse experiment:
Mice weremonitored until the onset of cachexia (15e21 days after tumor
cell inoculation). Body weight was measured at regular intervals.
Orthotopic mouse model (PDAC): 10 week old male C57BL6/J mice
were obtained from Charles River Laboratories (CRL, Brussels, BE).
Anesthetized mice treated with 5 mg/kg Carprofen as analgesia were
injected with 3000 cells (PDAC cell line #8024 or #8025; kind gift from
Dieter Saur, TU Munich, Germany) into the pancreas. Mice were
monitored until the onset of cachexia (24e26 days after tumor cell
inoculation). Body composition was determined once a week. Body
weight was measured in regular intervals.
Genetic mouse model (APC delta 580 mice): APC delta 580 mice on a
C57BL6/N background were originally purchased from the National
Cancer Institute (NCI) at Frederick (Frederick, MD, USA) and bred at the
Animal Facility of the German Cancer Research Center (DKFZ;
Heidelberg, Germany). Heterozygous APC delta 580 male mice and
age-matched wild-type C57BL/6N mice with an age of 14 weeks were
monitored until the onset of cachexia (at 4e6 months of age). Cardiac
performance which was measured by echocardiography and body
weight were determined in regular intervals.
Diabetic mice: 9e11 week old female ob/ob and db/db mice were
obtained from Charles River Laboratories (CRL, Brussels, BE). After 1
week, mice were sacrificed in random fed state.
A detailed description of general animal handling, hemodynamic
measurement techniques and histology can be found in the supple-
mental material. The animal care and all experimental protocols were
reviewed and approved by local authorities (Regierungspräsidium
Karlsruhe, Germany; G23/08; G12/06; G73/11; G178/13).
2.3. Cell culture
Cell lines were regularly tested for mycoplasma contamination by the
company Multiplexion using Multiplex Cell Contamination Test (McCT)
[21].
2.4. Preparation of conditioned supernatants (SN)
C26, MC38 (kind gift from C. Bourquin, Clinical Pharmacology, Munich,
Germany) and HEK293A cells (ATCC, Manassas, VA, USA) were plated
onto 15 cm plates and after reaching a confluency of w50% culture
medium (DMEM high glucose, 10% FBS, 1% Pen/Strep) was changed.
After 48 h, media were collected and the remaining cells were pelleted
by centrifugation. For the treatment of cardiomyocytes, conditioned SN
was 3:1 diluted in fresh culture medium. A detailed description of used
transfection procedures can be found in the supplemental material.
2.5. Primary neonatal rat cardiomyocytes
Hearts were isolated from male and female Wistar rats at the age of 1e2
days. Heart slices were digested in 0.1% pancreatin. To reduce the
amount of non-cardiomyocyte like epithelial cells and fibroblasts, cells
were pre-plated on 15 cm plates. Afterward, cells were harvested,
counted and finally plated on cell culture plates that were coated with
0.1% gelatin (BD, Heidelberg, Germany). Cells were cultured in DMEM
high glucose supplemented with 10% FBS and 1% Pen/Strep. After 3
days of plating cells were treated with conditioned SN for 24 h. A detailed
description of the high throughput analysis of cardiomyocyte size and
immunofluorescence staining can be found in the supplemental material.is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1: Cancer cachexia induces remodeling of the heart (A) Heart weight (HW)/tibia length (TL) ratio for control (Ctrl) and C26 bearing mice (C26) (n¼ 6 animals in Ctrl group,
n ¼ 10 animals in C26 group). (B) Representative overview images of H&E stained heart cross-sections of a control (Ctrl) and a C26 bearing mouse (C26). (C) Quantification of car-
diomyocyte cross-sectional areas for control (Ctrl) and C26 bearing mice (C26) (n 100 cardiomyocytes per heart; n¼ 5 hearts per group). (D) Fractional shortening (FS) for control (Ctrl)
and C26 bearing mice (C26) determined by using Vevo 2100 (n¼ 6 animals in Ctrl group, n¼ 10 animals in C26 group). (A)e(D)Mice were sacrificed on day 21 post PBS (Ctrl) and C26
cell injection. (E) Heart weight (HW)/tibia length (TL) ratio for control (Ctrl) and MC38 carryingmice (MC38) (n¼ 8 animals in Ctrl group, n¼ 10 animals in MC38 group). (F) Representative
overview images of H&E stained heart cross-sections of a control (Ctrl) and aMC38 bearingmouse (MC38). (G) Total heart weight (HW) of wild-type (APCþ/þ) and APC delta 580 (APC580/þ)
mice (n¼ 6 animals in APCþ/þ group, n¼ 8 animals in APC580/þ group). (H)Representative overview images of H&E stained heart cross-sections of a wild-type (APCþ/þ) and an APC delta
580 (APC580/þ) mouse. (I) Quantification of cardiomyocyte cross-sectional areas of wild-type (APCþ/þ) and APC delta 580 (APC580/þ) mice (n  100 cardiomyocytes per heart; n ¼ 4
hearts per group). (A), (C), (D), (E), (G) and (I) Data are means  SEM. *indicates significance using Student’s t-test with Welch correction, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 2: Tumor-borne secreted factors mediate cardiomyocyte atrophy and alter cardiomyocyte fatty acid metabolism. (A) Immunofluorescence staining of a-actinin in
neonatal rat cardiomyocytes cultured in standard medium (Ctrl) or conditioned medium from C26, MC38 and HEK293A cells for 24 h, respectively (Magnification: 20). (B) Relative
cross-sectional areas of neonatal rat cardiomyocytes of the experiment shown in (A) (n  100 cardiomyocytes per condition). (C) Top hits (black) of KEGG pathway analysis of
genes differentially regulated in primary adult mouse cardiomyocytes after treatment with conditioned medium from C26 cells for 48 h (n ¼ 3 cell culture wells per group). (D)
Relative mRNA level of lipoprotein lipase (Lpl), fatty acid transporter 4 (Fatp4), fatty acid transporter 6 (Fatp6), fatty acid translocase (FAT/CD36), carnitine palmitoyltransferase 1a
(Cpt1a), acyl-CoA dehydrogenase, very long chain (Acadvl), hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA hydratase (Hadha), diglyceride acyltransferase 1
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2.6. Primary adult mouse cardiomyocytes
Hearts from9 to 10week old anesthetized Balb/cmalemicewere excised
and mounted on a Langendorff perfusion apparatus. A retrograde
perfusion with nominally Ca2þ-free Tyrode’s solution (pH 7.42) followed
by a perfusion with digestion buffer (Tyrode’s solution containing 4mg/ml
liberase 1 (Roche, Mannheim, Germany), trypsin 0.6% and 0.125 mM
CaCl2) was performed. After digestion, ventricular tissue was cut,
dispersed, and filtered, and cells were pelleted. Cell pellet underwent a
Ca2þ reintroduction (0.1, 0.2, 0.4 and 0.8 mM). Afterward, cell pellet was
resolved in plating medium (MEM/HBSS medium containing 2 mM
glutamine, 1% Pen/Strep, 10% FBS, 10 mM BDM and 2 mM Na-ATP),
and cardiomyocytes were plated at 50,000 rod-shaped myocytes/well
on laminin-coated 6-well plates. After 1 h, plating medium was removed
and cardiomyocytes were treated with conditioned SN for 48 h. A detailed
description of engineered heart tissue (EHT) and immunofluorescence
staining can be found in the supplemental material.
2.7. Quantitative secretome analysis
C26 as well as MC38 cells were grown on two 10 cm cell culture
dishes until they reached 60e70% confluency. Cells were cultured in
SILAC medium (DMEM (non-GMP formulation w/o met, arg and lys),
10% FBS (dialyzed), 4 mM L-Glutamine, 100 mg/l Primocin) for 30 min
(4 ml per dish). Subsequently, cells were incubated for 24 h in SILAC
medium supplemented with 0.1 mM L-azidohomoalanine (AHA) and
either 84 mg/ml [13C6,
15N4] L-arginine and 146 mg/ml [
13C6,
15N2] L-
lysine (heavy label) or 84 mg/ml [13C6] L-arginine and 146 mg/ml
[4,4,5,5-D4] L-lysine (intermediate label). Experiments were performed
as independent biological duplicates with reversed SILAC labels. Media
were collected, centrifuged, supplemented with protease inhibitor
(Roche, Mannheim, Germany) and frozen at 80 C. Enrichment of
newly synthesized proteins, sample preparation for mass spectrom-
etry, liquid chromatography tandem mass spectrometry (LC/MS), data
analysis and statistics were performed as previously described [22].
2.8. Extracellular flux analysis
Neonatal rat cardiomyocytes were seeded at 5  104 per well onto an
XF96 PS microplate (Seahorse Bioscience, Copenhagen, DK), which
was coated with 0.1% gelatin. Cardiomyocytes were exposed to
conditioned SN 24 h prior to the analysis. Then medium was changed
to the respective assay medium. Assays were performed according to
manufacturers’ instructions (Seahorse Bioscience, Copenhagen, DK).
Mitochondrial Stress test: Assay compounds were used at the
following final concentrations: 2 mM oligomycin, 0.3 mM FCCP, 1 mM
rotenone and 1 mM antimycin A. Palmitate Uptake Assay: 10 mM
sodium palmitate (Sigma, #P9767) was coupled to fatty-acid free BSA
(Sigma, #A8806). Both BSA-palmitate conjugate solution and beta-
oxidation inhibitor etomoxir were added at a final concentration of
1 mM. Mitochondrial function assessed by oxygen consumption rate
(OCR) was normalized to cell density (absorbance) determined by
Sulforhodamine B staining.(Dgat1), acyl-CoA synthetase long-chain family member 1 (Acsl1) and acetyl-CoA acetyltra
conditioned medium from C26 cells (n ¼ 4 cell culture wells per group). (E) Palmitate-dri
conditioned medium for 24 h (n ¼ 9 cell culture wells for Ctrl group, n ¼ 15 cell culture
(OCR; means  SEM). 1 mM BSA-conjugated palmitate and 1 mM etomoxir were added
diomyocytes cultured in standard medium (Ctrl) or C26 conditioned medium (C26) for 2
diomyocytes cultured in standard medium (Ctrl) or C26 conditioned medium (C26) for 24
Mitochondrial function is expressed by oxygen consumption rate (OCR; means  SEM). 2 m
added at the indicated time points. (B), (D) and (F) Data are means  SEM. *indicate
***p < 0.001. (E) and (G) Data are means  SEM. *indicates significance using 2-way
MOLECULAR METABOLISM- (2015) 1e12  2015 The Authors. Published by Elsevier GmbH. This is an ope
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Total RNA was extracted from frozen organ samples or cardiomyocytes
using Qiazol reagent and RNeasy kit (Qiagen, Hilden, Germany). cDNA
was prepared by reverse transcription using M-MuLV enzyme and
Oligo dt primer (Thermo Scientific, Schwerte, Germany). cDNAs were
amplified using assay-on-demand kits and a StepOne Real-time PCR
system (Life Technologies, Darmstadt, Germany). RNA expression data
were quantified according to the delta CT method as described [23]
and normalized to RNA levels of TATA-box binding protein (TBP).
2.10. Gene expression profiling
RNA isolation was performed as described before. cDNA and cRNA
synthesis and hybridization to arrays of type Mouse Genome 430 2.0
from Affymetrix were performed according to the manufacturer’s rec-
ommendations. A Custom CDF Version 14 with Entrez based gene
definitions was used to annotate the arrays. The Raw fluorescence
intensity values were normalized applying quantile normalization. Dif-
ferential gene expression was analyzed based on loglinear mixed model
ANOVA (Hsieh W.P., 2003; Roy J., 2007), using a commercial software
package SAS JMP7 Genomics (version 4) from SAS (SAS Institute,
Cary, NC, USA). A false positive rate of a¼ 0.05 with false discovery rate
(FDR) correction was taken as the level of significance. The over-
representation analysis (ORA) is a microarray data analysis that uses
predefined gene sets to identify a significant overrepresentation of
genes in data sets [24]. Pathways belonging to various cell functions
were obtained from public external databases (KEGG, http://www.
genome.jp/kegg/). A Fisher’s exact test was performed to detect the
significantly regulated pathways. Gene Set Enrichment Analysis (GSEA)
was used to determine whether defined lists (or sets) of genes exhibit a
statistically significant bias in their distribution within a ranked gene list
(http://www.broadinstitute.org/gsea/; [24]).
2.11. Enzyme-linked immunosorbent assay (ELISA)
Levels of human and murine Ataxin-10 were determined in conditioned
SNs and sera using pre-coated Sandwich-ELISA (Uscn Life Science,
Wuhan, CA). Assays were performed following the manufacturer’s
instructions. Conditioned SNs and human sera were measured undi-
luted and mouse serum was diluted 1:10/1:20.
2.12. Human subjects
Human serum samples and clinical data of patients with pathologically
confirmed pancreatic ductal adenocarcinoma were derived from the
prospective biobank and database of the European Pancreas Center
(EPC), Department of General Surgery, Heidelberg University Hospital
and were collected as approved by the local ethics committee.
Ataxin-10 (Atxn10) serum levels were determined in pre-surgery
serum samples by using pre-coated Sandwich-ELISA (Uscn Life Sci-
ence, Wuhan, CA, USA). Atxn10 serum levels were compared between
control groups of patients with pancreatic ductal adenocarcinoma
(PDAC) without cachexia (defined according to consensus classification
from 2011 [25]), which did or did not receive neoadjuvant radio- and/ornsferase 2 (Acat2) in neonatal rat cardiomyocytes cultured in standard medium (Ctrl) or
ven oxidation of neonatal rat cardiomyocytes cultured in standard medium (Ctrl) or C26
wells for C26 group). Mitochondrial function is expressed by oxygen consumption rate
at the indicated time points. (F) Uptake of 3H labeled palmitate by neonatal rat car-
4 h (n ¼ 6 cell culture wells per group). (G) MitoStress testing of neonatal rat car-
h (n ¼ 10 cell culture wells for Ctrl group, n ¼ 15 cell culture wells for C26 group).
M oligomycin, 0.3 mM FCCP and 1 mM rotenone together with 1 mM antimycin A were
s significance using Student’s t-test with Welch correction, *p < 0.05, **p < 0.01,
ANOVA, Bonferroni post-test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 3: Quantification of pro-cachectic factors and analysis of their atrophy-inducing potential. (A) and (B) Quantification of secreted proteins comparing cachexia-
inducing C26 cells and non-cachexia-inducing MC38 cells. (A) Number and overlap of proteins quantified in the two biological replicates. (B) Pearson correlation between the
two biological replicates is 0.93. 271 of 893 proteins quantified in both replicates show significant differences between the two cell lines (red). 28 of the 129 proteins stronger
secreted by C26 cells can induce atrophy (green, blue and yellow). 7 of these additionally induce a metabolic phenotype (blue and yellow). (C) Histogram of the 384-well high
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chemotherapy (referred to as neoTx) and groups of PDAC patients with
cachexia, which did or did not receive neoTx. Clinico-pathological data
include tumor characteristics, therapy and weight loss and are pro-
vided in Table 3.
2.13. Statistical analysis
For each experiment, means  SEM were determined. Statistical
analysis was performed with GraphPad Prism (Version 5.0, GraphPad
Software Inc., CA, USA). Statistical analyses were performed using
student’s t-test (Welch’s test), 1-way ANOVA or 2-way ANOVA where
appropriate. Correlation was determined using Spearman correlation
coefficient. p < 0.05 was considered statistically significant.
3. RESULTS
3.1. Distinct colon cancer cell lines exert differential impacts on
cardiac dysfunction
Cardiac dysfunction has been described as a severe complication in
the cachectic state as induced by different cancer entities in both
experimental animals and humans, including tumors of the colon, the
lung, and the pancreas [15,17].
To initially delineate the cachexia-inducing properties of distinct tumor
cell models in vivo, we employed comparative metabolic phenotyping
in mice using the well-established cachexia-inducing colon (C) 26 and
non-cachexia-inducing murine colon (MC) 38 adenocarcinoma trans-
plantation models [26,27]. Three weeks after cell transplantation,
subcutaneous implantation of C26 cells into wild-type mice promoted a
roughly 10% loss of body weight (Figure S1A), which was associated
with loss of skeletal muscle and adipose tissue mass and decreased
food intake as reported previously (Figure S1BeD) [14]. Importantly,
C26 tumors triggered a significant loss of heart weight (Figure 1A) with
a gross reduction in heart size (Figure 1B) and cardiomyocyte diameter
(Figure 1C) as compared with healthy control littermates. Notably,
while no cardiac fibrosis was evident in cachectic animals
(Figure S1EeH), the observed atrophy was associated with impairment
of cardiac function assessed by echocardiography (Figure 1D) and of
other hemodynamic parameters as determined by pressure-volume
(PV) loop measurements (Figure S2AeI).
In contrast, transplantation of MC38 colon cancer cells and subsequent
tumor formation in wild-type animals had no effect on body weight and
fat and skeletal muscle mass as compared to non-tumor-bearing lit-
termates (Figure S3AeC). Also, MC38 tumor formation did not affect
heart weight and size (Figure 1E,F; Figure S3D) nor cardiac function in
these animals (Figure S3E), indicating that the MC38 adenocarcinoma
intrinsically lacks pro-cachectic properties and functionality as
compared with the C26 colon cancer model in vivo.
To verify our findings in the C26 model in an independent genetic
model of colon cancer-induced cachexia, we employed animals car-
rying the adenomatous polyposis coli (APC) mutation, the most com-
mon human mutation associated with colorectal cancer [28]. APC
mutant animals developed numerous intestinal lesions at 5e6 month
of age [29]. Lesion appearance triggered a significant reduction in body
weight, skeletal muscle and WAT mass and anemia (Figure S3FeI),
thereby mimicking the observed cachectic features in the C26throughput screening showing the areas of neonatal rat cardiomyocytes cultured in stan
untreated HEK293A cells and HEK293A cells þ cDNA clone: 14 (Fabp5), 15 (Psap), 18 (Lga
medium from C26 cells and HEK293A cells þ cDNA Clone: 5 (Ccl2), 9 (Nptx1), 21 (Adam1
(App), 49 (Ywhaq), 52 (Cst6), 57 (Gaa), 75 (Timp2), 79 (B4galt1), 80 (Trim25), 83 (Minpp1),
(Adamtsl4), 105 (Arsb) or 109 (Col8a1)). (n ¼ 6e9 cell culture wells per condition).
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displayed reduced heart weight and size as well as impaired cardiac
function with no signs of fibrosis (Figure 1GeI; Figure S3JeL), thus
validating cardiac atrophy and dysfunction in an independent experi-
mental setting of colon cancer.
3.2. Cardiomyocyte atrophy is induced through tumor-borne
secreted factors in a cell-autonomous manner
Our results thus far suggested that cardiac atrophy represents an
important read-out parameter in systemic cancer cachexia with dif-
ferential responsiveness to distinct colon cancer cell types.
To test whether the cachexia-inducing effect of C26 colon cancer cells
is mediated by tumor-borne factors in a cell-autonomous fashion and
to exclude host-derived, secondary signals, we developed an in vitro
cardiomyocyte phenotyping system. To this end, primary car-
diomyocytes were isolated from either neonatal rats or adult wild-type
mice, plated onto multi-well cell culture plates, and exposed to
conditioned supernatants (SN) from colon cancer and non-tumor
control cell lines. Consistent with the cardiac phenotypes in vivo
(Figure 1), exposure of primary cardiomyocytes to C26 conditioned SN
triggered a substantial reduction of cardiomyocyte size in both
neonatal rat and adult mouse cardiomyocytes, respectively
(Figure 2A,B; Figure S4A,B). In contrast, neither MC38 nor HEK293A
non-tumor SN caused cardiomyocyte atrophy under these conditions
(Figure 2A,B), suggesting that C26 colon cancer cells specifically
release pro-cachectic mediators that can cause cardiac atrophy in a
cell-autonomous manner. In support of this notion, exposure of car-
diomyocytes to serum of C26-carrying cachectic mice provoked
cellular atrophy in vitro, the strength of which was correlating with the
progression of cachexia in the donor mice (Figure S4C).
To further define the molecular-metabolic properties of cachectic
cardiomyocytes, we performed comparative, high throughput tran-
scriptome analysis in hearts from C26 tumor-carrying animals as
compared with non-tumor bearing littermates and C26 SN-exposed
primary mouse cardiomyocytes as compared with control SN.
Remarkably, fatty acid (FA) metabolism appeared amongst the most
significantly regulated gene pathways in atrophic cardiomyocytes
(Figure 2C), and several genes involved in FA transport, oxidation and
storage were found to be dysregulated in response to C26 SN in pri-
mary neonatal rat cardiomyocytes as demonstrated by altered mRNA
levels (Figure 2D), thus confirming the in vivo data (Figure S4D,E).
To explore the impact of C26 SN on cardiac FA metabolism also at the
functional level, we performed metabolic flux analyses in primary
neonatal rat cardiomyocytes using Seahorse technology. Consistent
with a reduced lipid storage capacity in both C26 SN-exposed isolated
neonatal rat cardiomyocytes (Figure S5A) and hearts from C26
transplanted animals (Figure S5B), palmitate-driven FA oxidation in
cardiomyocytes was significantly elevated in response to C26 SN as
compared with controls (Figure 2E), correlating with a tendency to
enhance cellular FA uptake under these conditions (Figure 2F). Note-
worthy, mitochondrial stress testing revealed an increased maximal
respiratory capacity in cardiomyocytes exposed to C26 SN (Figure 2G).
These findings supported the hypothesis that atrophic cardiomyocytes
switch to an energy-wasting mode in response to pro-cachectic cancerdard medium (Ctrl), under non atrophy-inducing conditions (conditioned medium from
ls3bp), 70 (Dpysl2) or 74 (Hspa13)) and under atrophy-inducing conditions (conditioned
5), 25 (Asah1), 26 (Tpp1), 28 (Yars), 29 (B2m), 36 (Cpe), 37 (Fscn1), 44 (Efemp2), 45
84 (Stx7), 87 (Bin1), 88 (Ddb1), 91 (Atxn10), 95 (Mmp2), 99 (Uxs1), 101 (Zc3hav1), 104
n access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 4: Selective cachexokines provoke aberrant fatty acid metabolism in
cardiomyocytes. (A) Palmitate-driven oxidation of neonatal rat cardiomyocytes cultured
in standard medium (Ctrl), conditioned medium from C26 cells or HEK293A cells that
were either untreated (HEK293A) or over-expressed one of the selective “cachexokines”
(Adamts like 4 (Adamtsl4), Chemokine ligand 2 (Ccl2), Glucosidase alpha acid (Gaa),
Multiple inositol-polyphosphate phosphatase 1 (Minpp1), Syntaxin 7 (Stx7), Bridging
integrator 1 (Bin1) and Ataxin-10 (Atxn10)) for 24 h (n¼ 5 cell culture wells for Ctrl, C26,
HEK293A, Gaa and Stx7 group, n¼ 6 cell culture wells for Adamtsl4, Ccl2, Minpp1, Bin1
and Atxn10 group). Mitochondrial function is expressed by oxygen consumption rate
(OCR; means  SEM). 1 mM BSA-conjugated palmitate and 1 mM etomoxir were added
Original article
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combined atrophic and metabolic changes in response to tumor cell
SN, we employed engineered heart tissue (EHT) [30] in combination
with enriched tumor cell SN. In congruence with a functional impair-
ment in contractile heart function in vivo (Figure 1D; Figure S2),
exposure of EHT to cachexia-inducing C26 SN diminished the con-
tractile properties of the EHT (Figure S5C,D), thereby further sub-
stantiating the conclusion that cachexia-inducing colon cancer cells
can directly impair cardiac function through secreted factors, i.e.
cachexokines.
3.3. A signature of seven secreted proteins acts in a combined
manner to provoke cardiac atrophy and aberrant FA oxidation
The previous experiments indicated that cachectic cardiomyocytes are
characterized by two distinct features, namely reduced cell size and
aberrant FA oxidation, both triggered through tumor-borne factors
intrinsic to C26 but not to MC38 colon cancer cells. Indeed, heat
inactivation prevented the atrophy induction by C26 SN, and with-
drawal of C26 conditioned medium recovered the atrophic phenotype
in cardiomyocytes (Figure S5E,F), overall suggesting that the cellular
atrophy is largely conferred through protein mediators. Given the
clinical importance of potential cachexokines for preventive, diagnostic
and therapeutic applications, these findings prompted us to employ
unbiased differential secretome analysis of C26 and MC38 tumor cells.
To this end, we combined click chemistry and pulsed stable isotope
amino acid labeling in both C26 and MC38 cells to selectively enrich
and quantify secreted proteins from both cell lines. The combination of
these two labeling approaches allows the identification of secreted
proteins irrespective of the complexity of the background proteins, and
thus the use of optimal growth conditions (i.e. the presence of serum)
[22]. Mass-spectrometry-based identification of C26 and MC38
secretomes and differential secretome mapping established a total of
893 reproducibly secreted proteins from either C26 or MC38 cells,
respectively (Figure 3A). Out of these factors, 129 proteins were found
to be at least 2-fold more abundant in the C26 secretome as compared
with MC38, while 142 proteins were at least 2-fold more abundant in
the MC38 secretome (Figure 3B; Table 1).
We hypothesized that amongst the 129 secreted proteins with relative
enrichment in cachexia-inducing C26 tumors, individual or a combi-
nation of secreted proteins would be able to impose the cardiac
cachectic phenotype described above (Figure 2).
To directly test the pro-cachectic potential of identified candidates in
an unbiased fashion, we obtained cDNA clones and over-expressed
109 candidates (Table 2) in non-cancerous HEK293A cells
(Figure S5G). Candidate-enriched SN (Figure S5H) from these cells was
collected and assayed for its atrophy-inducing potential on primary
neonatal rat cardiomyocytes using a high throughput, automated 384-
well screening format. In congruence with our hypothesis, SN from 28
out of 109 transfected cell clones indeed caused cardiomyocyte at-
rophy in repeated screening rounds (Figure 3C), and their impact onat the indicated time points. (B) Palmitate-driven oxidation of neonatal rat car-
diomyocytes cultured in standard medium (Ctrl), conditioned medium from untreated
C26 cells or C26 cells that were treated with either negative control (NC) siRNA or siRNAs
directed against all 7 remaining candidates (siRNA) for 24 h (n ¼ 7 cell culture wells for
NC and siRNA group, n ¼ 9 cell culture wells for Ctrl and C26 group). (C) MitoStress
testing of neonatal rat cardiomyocytes cultured as described for (B) (n ¼ 10 cell culture
wells per group). Mitochondrial function is expressed by oxygen consumption rate (OCR;
means  SEM). 2 mM oligomycin, 0.3 mM FCCP and 1 mM rotenone together with 1 mM
antimycin A were added at the indicated time points.
is is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 5: SerumAtaxin-10 levels are elevated under cachectic conditions. (A)e(D) Ataxin-10 (Atxn10) serum levels in differentmousemodels: (A)C26 (n¼ 6 animals in Ctrl group,
n¼ 9 animals in C26 group), (B)MC38 (n¼ 3 animals in Ctrl group, n¼ 4 animals in MC38 group), (C) APC delta 580 (n¼ 5 animals in APCþ/þ group, n¼ 6 animals in APC580/þ group)
and (D) SW480 (n¼ 3 animals in Ctrl group, n¼ 6 animals in SW480 group). (E) Ataxin-10 (Atxn10) serum levels inwild-typemice (Ctrl) andmice withmild (mean bodyweight loss: 2.5%)
and strong (mean body weight loss: 17%) cachectic phenotype that underwent orthotopic implantation of pancreatic cancer cells (n ¼ 7 animals in Ctrl group, n ¼ 6 animals in mild
cachectic group, n¼ 5 animals in strong cachectic group). (F) Spearman correlation of Ataxin-10 (Atxn10) serum level and body weight loss (%) in the pancreatic orthotopic implantation
mouse model (Coefficient (coeff.) ¼ 0.831), p-value: 2  107). (G) Ataxin-10 (Atxn10) serum levels in pancreatic ductal adenocarcinoma patients (PDAC) without cachexia and
neoadjuvant therapy (neoTx) (Ctrl), PDAC patientswithout cachexia but neoTx (Ctrl (neoTx)), PDAC patients with cachexia butwithout neoTx (Cachexia) and PDAC patientswith cachexia and
neoTx (Cachexia (neoTx)) (n¼ 24 patients in Ctrl group, n¼ 8 patients in Ctrl (neoTx) group, n¼ 10 patients in Cachexia group, n¼ 10 patients in Cachexia (neoTx) group). (A)e(D) Data
are means SEM. *indicates significance using Student’s t-test with Welch correction, *p< 0.05. (E) Data are means SEM. *indicates significance using 1-way ANOVA, Bonferroni
post-test, compared to Ctrl group, ***p < 0.001. (G) Data are means  SEM. *indicates significance using 1-way ANOVA, Tukey’s multiple comparison test, compared to Ctrl group,
*p < 0.05, ***p < 0.001. $indicates significance using 1-way ANOVA, Tukey’s multiple comparison test, compared to Ctrl (neoTx) group, $$p < 0.01.
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Original articlecardiomyocyte size could be validated by subsequent small-scale
in vitro phenotyping as described above (Figure S5I). Next, the
selected C26-derived secreted proteins were further filtered for their
potential impact on cardiac FA oxidation as determined by metabolic
flux analysis in primary neonatal rat cardiomyocytes. As shown in
Figure 4A, enriched SN from 7 out of 28 bona fide atrophy-inducing
mediators (Bridging integrator 1 (Bin1), Syntaxin 7 (Stx7), Multiple
inositol-polyphosphate phosphatase 1 (Minpp1), Glucosidase alpha
acid (Gaa), Chemokine ligand 2 (Ccl2), Adamts like 4 (Adamtsl4) and
Ataxin-10 (Atxn10) e enhanced palmitate-driven FA oxidation, thereby
mimicking the dual effect of full C26 SN in terms of cardiomyocyte size
reduction and FA metabolism (Figure 4A; Figure S6A).
These experiments thus identified a signature panel of 7 cachexokines
that were sufficient as individual factors to drive cardiomyocyte
dysfunction in response to colon cancer growth independent from
secondary host responses.
To next determine whether individual cachexokines were not only
sufficient but also necessary to promote a cardiac cachectic pheno-
type, we employed siRNA-based knockdown strategies to silence the
expression of the identified cachexokine signature panel in C26 colon
cancer cells. Remarkably, SN from C26 cells depleted in individual
cachexokines (Figure S6B) still promoted cellular atrophy of primary
neonatal rat cardiomyocytes as compared with SN from control siRNA-
transfected or parental C26 cells. In addition, individual cachexokine
deficiency in C26 colon cancer cells did not improve the fatty acid
metabolism phenotype, promoting the conclusion that individual
cachexokines although sufficient to trigger a cardiac cancer cachectic
phenotype may normally be required to act in a combinatorial fashion
to confer a full cachectic response. Indeed, simultaneous ablation of all
seven cachexokines in C26 colon cancer cells (Figure S6C) was able to
prevent the SN-induced dysmetabolic phenotype in isolated car-
diomyocytes as compared with the parental or control siRNA-
transfected C26 SN (Figure 4B,C), underlining the notion that the
seven cachexokines act in a combinatorial manner to specifically target
cardiomyocyte function and metabolism during cancer cachexia.
3.4. Ataxin-10 correlates with weight loss in murine cachexia
models and marks cachexia in cancer patients
In order to provide proof-of-concept and to test for a potential signif-
icance of a prototype cachexokine to serve as diagnostic and/or
prognostic marker, we screened the serum levels of Ataxin-10, which
had initially been shown to display the most robust differential
secretion between C26 and MC38 colon cancer cells (Figure 3B;
Table 1; Figure S7A,B) in a variety of cancer cachexia mouse models.
Consistent with the pro-cachectic properties of Ataxin-10-enriched SN
in cellular co-culture studies, serum levels of Ataxin-10 were elevated
in C26-carrying mice and APC mutant mice but not MC38 carrying
mice (Figure 5AeC), correlating with the cachectic and non-cachectic
phenotype, respectively. Importantly, Ataxin-10 serum levels were also
induced 4-fold in an additional independent cachexia model using
human SW480 colon cancer cells in a SCID mouse background
(Figure 5D). Intriguingly, tumor-induced cachexia mediated by ortho-
topic implantation of pancreatic cancer cells into C57BL6 wild-type
mice (Figure S7CeE) led to an up to 6-fold elevation of circulating
Ataxin-10 levels, which tightly correlated with the degree of body
wasting (Figure 5E,F), indicating that the elevation of Ataxin-10 serum
levels may serve as a prognostic/diagnostic biomarker for both murine
as well as human colon cancer. Interestingly, Ataxin-10 levels were
also significantly elevated in two mouse models of obesity and type 210 MOLECULAR METABOLISM- (2015) 1e12  2015 The Authors. Published by Elsevier GmbH. Thdiabetes (Figure S7F,G), suggesting that this marker might also be
indicative of cardiac dysfunction under distinct metabolic conditions
that resemble the cancer cachectic phenotype [31].
To finally explore the validity of this hypothesis in humans, we
determined Ataxin-10 serum levels in a cohort of cachectic and non-
cachectic pancreatic cancer patients (Table 3). Of note, Ataxin-10
levels were significantly elevated in serum from cachectic patients
that were untreated or received neoadjuvant radio- and/or chemo-
therapy (RTx, CTx) as compared to weight stable subjects that were
either treated with radio- and/or chemotherapy or untreated
(Figure 5G), overall demonstrating that Ataxin-10 represents a proto-
typical and conserved member of the cardiac-directed cachexokine
signature that imposes cardiac atrophy, contractile dysfunction and
aberrant lipid metabolism in cancer cachexia and may serve as a
prognostic factor in human cancer cachectic patients.
4. DISCUSSION
Cancer cachexia represents a severe clinical condition for which no
effective diagnostic, preventive or therapeutic measures are available
to date [6]. While it has become clear that metabolic disturbances play
a major role in the development of cachexia [16], and already classical
experiments suggested the presence of circulating pro-cachectic
factors [7], the rational identification of tumor-borne cachexokines
has been hampered by technological obstacles in the past decades [6],
including limitations in reliable detection methods in body fluids and
the absence of relevant phenotypic read-out systems.
Our studies now provide a first unbiased and functional screening
setup for the discovery of bona fide cachexokines with both sufficient
and necessary cachexogenic properties. In this context, the estab-
lished cardiomyocyte phenotyping system can potentially set the
framework for an in vitro diagnostic tool to predict and/or diagnose
pro-cachectic mediators in patient samples in a large-scale format.
Of note, the cardiomyocyte setting can be anticipated to monitor only a
subset of heart-specific “cachexokines”. Indeed, while the aim of our
current study was to specifically screen for heart-specific cachexia
signaling cues, the overall cachexokine profile from C26 cells may
represent a valuable starting point to interrogate the functionality of
additional factors in other tissue compartments.
In addition, it will be interesting to determine the interplay between our
newly identified mediators and previously described pharmacological
attempts to ameliorate tumor-induced cardiac cachexia [2], including
the beta-blocker bisoprolol and the aldosterone antagonist spi-
ronolactone. Given the obvious complexity of cachexia-triggering
signaling pathways, it will be interesting to determine potential
points of convergence amongst these divergent pathways to pinpoint
critical intracellular nodes in the cachectic cardiomyocyte.
Of note, impaired heart function is often associated with fibrosis, which
results in stiffness [32], and a number of other studies reported an
increase in cardiac fibrosis in the tumor-bearing situation [2,15,18].
However, in our study, neither induction of fibrosis nor a rise in
appropriate markers was observed. Also, trichrome staining did not
reveal an increase in collagen deposition in all animal models inves-
tigated. We speculate that the reasons for these discrepancies prob-
ably lie in the use of distinct C26 sub-clones and/or different degrees of
cachexia at the time of sacrifice. In addition, recent studies have
highlighted the importance of the immediate tumor environment (e.g.
subcutaneous vs. intraperitoneal implantation sites) for the cachexia-
inducing properties of a given tumor [33], which might also explainis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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seemingly contradictory observations with respect to a fibrotic
phenotype. However, we did observe a change in the type of collagens,
i.e. downregulation of collagen III and simultaneous upregulation of
collagen I. As a higher collagen I to III ratio leads to reduced tissue
function due to enhanced stiffness [34], it is tempting to speculate that
the imbalance of the two collagen types promotes the observed cardiac
dysfunction in our setting.
With respect to heart function, our studies indicate that alterations in
fatty acid and/or lipid metabolism represent distinct features of the
cachectic heart. In line with previous studies [35], it is tempting to
speculate that inefficient mitochondrial FA oxidation and an increased
uncoupling potential in cardiomyocytes, as previously described in
cachectic skeletal muscle [36], contributes to an energy deficient state
and ultimately cellular atrophy as observed by us and others [15,18]. In
any case, it will be mandatory to put cachexia-associated alterations in
FA oxidation into perspective with additional mechanisms contributing
to cardiac dysfunction in cachexia, most notably including the induc-
tion of autophagy [15], hypo-innervation [20], and altered mTOR
signaling [37]. However, while the molecular mechanisms of
cachexokine-induced FA metabolic dysfunction and its relative
contribution to a cachectic heart phenotype remain to be defined in
future studies, it is evident that “metabolocentric” therapeutic ap-
proaches clearly have to be considered more extensively to overcome
cardiac dysfunction and eventually mortality in cancer cachectic
patients.
At the systemic level, most cachectic phenotypes have been ascribed
to the combinatorial action of both tumor- and host-derived media-
tors, most notably including members of the cytokine family [38]. Our
results now raise the intriguing possibility that particular tumor-borne
cachexokine signatures indeed exist that are sufficient and necessary
to provoke a full-blown cachectic phenotype, independent from
secondary host responses. Considering that the combined but not the
single knockdown of 7 potential cachexokines was sufficient to
rescue the metabolic phenotype and that the combined knockdown
failed to prevent the cardiac atrophy, it can be hypothesized that the
overall cachectic phenotype is induced by combinatorial effects of
several tumor secreted factors, influencing very distinct aspects of
the overall pathology. Most clinical interventions have focused on
single pro-cachectic factors known for decades, and treatments with
long-term beneficial effects still do not exist. Our studies support the
notion that the development of new therapeutic targets could be
based on tumor-specific secretome profiles. In this respect, it is
tempting to speculate about the degree of secretome overlaps be-
tween different tumor entities. Indeed, while Ataxin-10 represents a
common feature of both colon and pancreatic tumor secretomes,
future experimental studies will need to define the secretomes of
other tumor entities to establish common or distinguishing signatures.
We hypothesize that tumor-specific secretome profiling and the
identification of cachectic pathways driven by specific cachexokine
signatures will increase the chance to find therapeutic modalities in
cancer cachectic patients, as previously exemplified by antagonism
against the high affinity activin type 2 receptor ActRIIB in skeletal
muscle atrophy [39,40]. These considerations should of course take
into account other systemic parameters including the impact of
chemotherapy as a confounding factor in many cancer cachectic
patients [41].
Given the relevance of our findings also for the human setting
(Figure 5), our study may pave the way for as yet unprecedented
diagnostic, preventive, and therapeutic approaches in cancer cachexia,
potentially using the Ataxin-10 marker as a valid starting point.
Noteworthy, as all tumor-induced pathophysiological features of theMOLECULAR METABOLISM- (2015) 1e12  2015 The Authors. Published by Elsevier GmbH. This is an ope
www.molecularmetabolism.comheart were also described for patients with heart failure [42], one
should consider adding the assessment of cardiac function to the list of
diagnostic criteria for cancer cachexia. The presented data show that
reduction in cardiac function occurred stepwise and already began in
the pre-cachectic state which could be used for the prognostic clas-
sification of tumor patients in the future.
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